Slide 1: Phylogica (ASX:PYC) Presentation
For personal use only Phylogica (ASX:PYC) Presentation By CEO Stephanie Unwin September 2017
Slide 2: Disclaimer
Disclaimer For personal use only The purpose of the presentation is to provide an update of the business of Phylogica Limited (ASX:PYC) [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc
Slide 3: About Us
About Us For personal use only Who are What do Why we? we do? Peptides? Perth-based biotech Improve existing drug Peptides are naturally focused on creating a delivery and identify occurring protein blocks in commercial platform carriers and cargoes the body with the to deliver drugs into from our p
Slide 4: Key Investment Highlights
Key Investment Highlights For personal use only • Addressing a large unmet market need - $250Bn for biologics targeting “undruggable” targets and $110Bn cancer treatment • Derisked investment opportunity - progressing 3 asset groups - intracellular delivery, biologic therapeutic solutions and new dr
Slide 5: Financial details
Financial details For personal use only Phylogica (ASX:PYC) share price August Current share price: $0.045 2016 -2017 0.06 0.05 Shares on issue: 2.12Bn 0.04 0.03 Market Cap: $95.4M 0.02 0.01 0 Cash : $9.5M
Slide 6: Experienced Management Team
Experienced Management Team For personal use only In mid 2017 Phylogica revitalised its management team with senior Pharma and commercial executives : Core Management Team Ms Unwin was previously an executive general manager at Dr Hayes was previously the Head of Biologics at Synergy. She has held s
Slide 7: Three focus areas to validate the commercial platform
Three focus areas to validate the commercial platform For personal use only Improve Functional Penetrating Peptides (FPP’s) endosomal escape activity 1 • New FPPs to be identified by assays • Protein engineering work Outcome: o Fine tuning existing FPPs active window and strategic substitution • 13
Slide 8: About Phylogica's FPPs
About Phylogica’s proprietary cell penetrating peptides which escape the endosome (our FPPs) can deliver a diverse For personal use only Phylogica’s FPPs range of “biologic cargoes” into cells overcome existing challenges to drug delivery Phylogica’s FPP FPPs attach to “biologic cargoes” (ie. such a
Slide 9: Best-in-class: Phylogica's FPP
Best-in-class: For personal use only 159-fold Phylogica’s FPP 37-fold 50 As conventional Cell Penetrating Peptides 40 (CPPs) are mostly trapped inside the cells, Drug Deliver Efficiency Phylogica’s FPPs: 30 (% +ve Cells) • Enable effective delivery of its biological cargoes as it enables the drug to
Slide 10: Commercial Opportunities: FPP
Commercial Opportunities: FPP For personal use only • Addressing the massive $250Bn (CAGR 10.6%) market of drug delivery • Improving delivery of existing/new drugs • FPPs form the basis of Phylomer Therapeutics with the potential to be a fully integrated drug delivery platform: o Compatible with wid
Slide 11: Biologic Cargoes: Targeting disease with Phylomer Peptides
For personal use only Biologic Cargoes Targeting disease with Phylomer Peptides
Slide 12: Our Lead Biological Cargo: iMyc
Our Lead Biological Cargo: iMyc For personal use only How is What is What is iMyc Myc? iMyc? effective? Cell Growth • PYC’s iMyc (Myc inhibitor) • Current Gold Standard reduces over-expressed OmoMyc protein Myc Metabolism Myc in cells, effectively • OmoMyc has low potency Apoptosis killing off the c
Slide 13: PYC's leading cancer therapeutic program: FPP-iMyc
PYC’s leading cancer therapeutic For personal use only program: FPP-iMyc • 7 out of 10 cancers involve an overactive Myc protein • Phylogica’s lead program FPP-iMyc is best-in-class • iMyc comparable or better than the ‘OmoMyc’ gold standard in killing Myc-addicted cells • Target market – $110 Bn Ne
Slide 14: Value inflection points: FPP-iMyc
Value inflection points: FPP-iMyc For personal use only Typical drug DRUG PRECLINICAL CLINICAL FDA APPROVAL discovery process DISCOVERY (animal testing) (human trials) Typical 5 years 1.5 years 6 years 1-2 years Timelines Determination Drug safety & Drug safety & Regulatory of a suitable efficacy in
Slide 15: Partnering Strategy
Partnering Strategy For personal use only Phylogica has a variety of academic and industry partnerships set up with key players in the industry working together to mine the Phylomer Library for new drug targets and to progress FPP’s with various ‘biological cargoes’.
Slide 16: Commercial Strategy milestones 2016-2018
2016 Commercial • Validation of FPP delivery technology For personal use only • Proof of concept triple delivery negative Strategy breast cancer cell line • Improved delivery of biologic cargoes into cells in vitro and in vivo • FPP-OmoMyc shown to reduce lymphoma cells in spleen and bone marrow 201
Slide 17: Thank you
For personal use only Thank you For more information contact Stephanie Unwin at stephanieu@phylogica.com